Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) CEO Fred Aslan sold 23,463 shares of the business’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $7.20, for a total transaction of $168,933.60. Following the transaction, the chief executive officer directly owned 1,519,606 shares in the company, valued at approximately $10,941,163.20. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Fred Aslan also recently made the following trade(s):
- On Monday, October 5th, Fred Aslan sold 61,696 shares of Artiva Biotherapeutics stock. The shares were sold at an average price of $6.84, for a total transaction of $422,000.64.
- On Tuesday, September 8th, Fred Aslan sold 23,429 shares of Artiva Biotherapeutics stock. The shares were sold at an average price of $10.92, for a total transaction of $255,844.68.
Artiva Biotherapeutics Stock Down 3.7%
Shares of Artiva Biotherapeutics stock traded down $0.27 during trading hours on Wednesday, hitting $7.00. 324,471 shares of the company’s stock traded hands, compared to its average volume of 393,273. Artiva Biotherapeutics, Inc. has a twelve month low of $2.71 and a twelve month high of $14.53. The stock has a 50 day simple moving average of $10.02 and a 200-day simple moving average of $9.23. The company has a market cap of $342.23 million, a PE ratio of -2.12 and a beta of 2.40.
Institutional Investors Weigh In On Artiva Biotherapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the company. State of Wyoming acquired a new position in shares of Artiva Biotherapeutics during the second quarter valued at about $45,000. Squarepoint Ops LLC bought a new stake in shares of Artiva Biotherapeutics during the second quarter valued at approximately $144,000. Spark Investment Management LLC acquired a new position in shares of Artiva Biotherapeutics in the second quarter valued at $160,000. Dimensional Fund Advisors LP bought a new position in Artiva Biotherapeutics in the first quarter worth $131,000. Finally, Sanctuary Advisors LLC bought a new position in Artiva Biotherapeutics in the first quarter worth $139,000.
Wall Street Analysts Forecast Growth
ARTV has been the subject of several recent research reports. Cantor Fitzgerald restated an “overweight” rating and set a $40.00 price target on shares of Artiva Biotherapeutics in a research report on Friday, October 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. HC Wainwright restated a “buy” rating on shares of Artiva Biotherapeutics in a research report on Friday, October 2nd. Finally, Wall Street Zen upgraded Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Artiva Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.
View Our Latest Research Report on ARTV
Artiva Biotherapeutics Company Profile
Artiva Biotherapeutics, Inc (NASDAQ:ARTV) is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is designed to produce off-the-shelf cell therapies that can be manufactured at scale and administered without using cells collected from each individual patient.
Artiva’s lead investigational product, AlloNK, also known as AB-101, is an allogeneic NK cell therapy being evaluated in combination with rituximab for autoimmune conditions, including systemic lupus erythematosus and lupus nephritis.
Further Reading
- Five stocks we like better than Artiva Biotherapeutics
- Skydance Just Became a Media Giant—With an $80 Billion Debt Load
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
